Stryker SYK pre-announced 4Q 2010 revenue of $1.995B, ahead of Oppenheimer/Street estimates, led by continued strength in MedSurg and accelerated growth in hips/knees. Management raised ex-charge EPS guidance for FY10 to $3.31-3.33 from $3.27-3.30.
According to Oppenheimer, for FY11, SYK expects constant currency growth of 11-13%. Ex-acquisition guidance of 5-7% constant currency sales growth is ahead of prior thinking. EPS guidance of $3.65-3.73 represents a 10-13% increase from 2010 levels, above Oppenheimer's previous $3.65. On the higher EBITDA outlook, it is raising the price target from $57 to $61.
Oppenheimer's Outperform thesis is predicated on improvements in MedSurg on thawing of
US hospital capital spending; better 2011 joint reconstruction performance with new product flow in hips and knees; increased gross margin flexibility as heavy compliance spend ends in mid-2011; balance sheet flexibility and greater product diversity than peers.
Oppenheimer has a $61 PT on SYK
SYK is trading higher at $58.37
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in